Not Yet Recruiting
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC
NCT07070713
- Conditions
- Immunotherapy, Metastatic Colorectal Cancer With Left-sided Primary Tumor
- Locations
-
- Fujian Cancer Hospital Fuzhou, Fujian, China